EP0807434A1 — Anti-inflammatory eyedrops
Assigned to Wakamoto Pharmaceutical Co Ltd · Expires 1997-11-19 · 28y expired
What this patent protects
Anti-inflammatory eyedrops comprising: (a)0.05 to 0.7 w/v % of diclofenac sodium; (b) 1 to 10 w/v % of γ-cyclodextrin; (c) 1 to 20 w/v % of polyvinylpyrrolidone; and (d) 0.002 to 0.01 w/v % of benzethonium chloride, or 0.002 to 0.005 w/v % of benzalkonium chloride; and having a p…
USPTO Abstract
Anti-inflammatory eyedrops comprising: (a)0.05 to 0.7 w/v % of diclofenac sodium; (b) 1 to 10 w/v % of γ-cyclodextrin; (c) 1 to 20 w/v % of polyvinylpyrrolidone; and (d) 0.002 to 0.01 w/v % of benzethonium chloride, or 0.002 to 0.005 w/v % of benzalkonium chloride; and having a pH value of 7.0 to 8.5. The eyedrops contain diclofenac sodium at a concentration over a wide range, remain stable for a long period of time, and little irritate the eyes.
Drugs covered by this patent
- Arthrotec (Diclofenac Sodium) · Pfizer
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.